Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe"

Immunobiology. 2012 Jun;217(6):590-2. doi: 10.1016/j.imbio.2011.11.001. Epub 2011 Nov 17.

Authors

Michael A Curran, Margaret K Callahan, Sumit K Subudhi, James P Allison

PMID: 22459268
DOI: 10.1016/j.imbio.2011.11.001

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / adverse effects*
CTLA-4 Antigen / antagonists & inhibitors*
Humans
Immunization, Passive / methods*
Ipilimumab
Melanoma / therapy*
Skin Neoplasms / therapy*

Substances

Antibodies, Monoclonal
CTLA-4 Antigen
Ipilimumab